Literature DB >> 8079105

Growth of the parathyroid glands in omeprazole-treated chickens.

R Gagnemo-Persson1, R Håkanson, F Sundler, P Persson.   

Abstract

BACKGROUND: Omeprazole, a long-acting inhibitor of gastric acid secretion, is able to increase the circulating concentrations of gastrin. Daily treatment with high doses of omeprazole cause sustained hypergastrinemia. Long-standing hypergastrinemia can be expected to exert numerous effects in the body. For instance, gastrin has been proposed to promote growth in the digestive tract and pancreas. The present study is concerned with the effect of omeprazole on parathyroid glands in the chicken.
METHODS: Chickens were treated with omeprazole (400 mumol/kg/day) in methylcellulose (2.5 ml/kg) for 5 or 10 weeks. Controls received vehicle. Blood calcium and serum gastrin concentrations were studied. The weight gain of the animals and of various organs (proventriculus, antrum, thyroids, parathyroids, ultimobranchial glands, and femur) were determined. The DNA content and the size of the parathyroid chief cells were also determined.
RESULTS: Omeprazole reduced the body weight gain while greatly increasing the weight of the proventriculus and the parathyroid glands. The weight and density of the femur were reduced. The circulating concentrations of calcium were unaffected. The DNA content of the parathyroid glands was increased, and morphometric analysis of the parathyroid chief cells showed an increased cell size. Thus, the increased parathyroid gland weight seems to reflect both hypertrophy and hyperplasia. There was a slight increase in the weight of the ultimobranchial glands (expressed per kilogram body weight). The weight of the thyroids was unaffected (expressed in relation to body weight).
CONCLUSIONS: The results indicate that omeprazole treatment in chickens leads not only to trophic effects in the acid-producing gastric mucosa (probably because of the ensuing hypergastrinemia), as reported earlier, but also to growth of the parathyroid glands (both hypertrophy and hyperplasia) and to bone loss without affecting blood calcium values. The mechanism behind these effects remains unknown.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8079105     DOI: 10.3109/00365529409092460

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  12 in total

1.  The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  Laura E Targownik; William D Leslie; K Shawn Davison; David Goltzman; Sophie A Jamal; Nancy Kreiger; Robert G Josse; Stephanie M Kaiser; Christopher S Kovacs; Jerilynn C Prior; Wei Zhou
Journal:  Am J Gastroenterol       Date:  2012-07-10       Impact factor: 10.864

2.  Hip fracture risk in patients with a diagnosis of pernicious anemia.

Authors:  Nathan A Merriman; Mary E Putt; David C Metz; Yu-Xiao Yang
Journal:  Gastroenterology       Date:  2009-12-21       Impact factor: 22.682

3.  Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.

Authors:  Chandan Vangala; Jingbo Niu; Colin R Lenihan; William E Mitch; Sankar D Navaneethan; Wolfgang C Winkelmayer
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-27       Impact factor: 8.237

Review 4.  Chronic proton pump inihibitor therapy and calcium metabolism.

Authors:  Yu-Xiao Yang
Journal:  Curr Gastroenterol Rep       Date:  2012-12

5.  Weight gain in mice on a high caloric diet and chronically treated with omeprazole depends on sex and genetic background.

Authors:  Milena Saqui-Salces; Amy C Tsao; Merritt G Gillilland; Juanita L Merchant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-03       Impact factor: 4.052

6.  Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.

Authors:  Giovanni Gori; Giacomo Spinelli; Claudio Spinelli; Marco Tuccori; Corrado Blandizzi; Mario Del Tacca
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

7.  Proton Pump Inhibitors and the Risk of Early Aseptic Loosening in Hip and Knee Arthroplasty.

Authors:  Iskandar Tamimi; Pablo Carnero; David Bautista; David Gonzalez; Pablo Rodrigo; María Jose Bravo; Abel Gómez; Faleh Tamimi; David Garcia de Quevedo
Journal:  Geriatr Orthop Surg Rehabil       Date:  2022-04-11

8.  A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study.

Authors:  Yunju Jo; Eunkyoung Park; Sang Bong Ahn; Young Kwan Jo; Byungkwan Son; Seong Hwan Kim; Young Sook Park; Hyo Jeong Kim
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519

Review 9.  Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: A review.

Authors:  Federica Cavalcoli; Alessandra Zilli; Dario Conte; Sara Massironi
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

Review 10.  Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved.

Authors:  Benjamin Ka Seng Thong; Soelaiman Ima-Nirwana; Kok-Yong Chin
Journal:  Int J Environ Res Public Health       Date:  2019-05-05       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.